

Prevention Strategies for Mpox, including Vaccinating People at Risk via Sexual exposure, for U.S. Travelers Visiting Countries with Clade I Mpox Outbreaks

DATE:	September 27, 2024
TO:	Health Alert Network
FROM:	Debra L. Bogen, M.D., FAAP, Secretary of Health
SUBJECT:	Prevention Strategies for Mpox, including Vaccinating People at Risk via Sexual Exposure, for U.S. Travelers Visiting Countries with Clade I Mpox Outbreaks
DISTRIBUTION:	Statewide
LOCATION:	Statewide
STREET ADDRESS:	N/A
COUNTY:	N/A
MUNICIPALITY:	N/A
ZIP CODE:	N/A

This transmission is a “Health Update” which provides updated information regarding an incident or situation; unlikely to require immediate action.

HOSPITALS: PLEASE SHARE WITH ALL MEDICAL, PEDIATRIC, NURSING AND LABORATORY STAFF IN YOUR HOSPITAL; **EMS COUNCILS:** PLEASE DISTRIBUTE AS APPROPRIATE; **FQHCs:** PLEASE DISTRIBUTE AS APPROPRIATE **LOCAL HEALTH JURISDICTIONS:** PLEASE DISTRIBUTE AS APPROPRIATE; **PROFESSIONAL ORGANIZATIONS:** PLEASE DISTRIBUTE TO YOUR MEMBERSHIP; **LONG-TERM CARE FACILITIES:** PLEASE SHARE WITH ALL MEDICAL, INFECTION CONTROL, AND NURSING STAFF IN YOUR FACILITY

Summary

- On September 23, 2024 the Centers for Disease Control and Prevention (CDC) issued a [Health Alert Network \(HAN\) Health Update](#) to provide additional information about the outbreak of monkeypox virus (MPXV) in the Democratic Republic of the Congo (DRC).
- As of September 18, 2024, >21,000 suspected clade I mpox cases have been identified in DRC, its largest annual number on record.
- Early data indicate that a large proportion of clade Ib mpox cases among adults has been [associated with sexual contact](#), including via ongoing transmission believed to be occurring in some countries where the virus is not normally found.
- Clinicians should discuss mpox prevention and risk reduction strategies with all travelers to countries with ongoing human-to-human transmission of clade I MPXV.
- Travelers to DRC or other countries with sustained spread of clade I mpox, regardless of sexual orientation or gender identity, should be made aware of activities associated with cases and should be vaccinated with two doses of JYNNEOS if they anticipate certain sexual exposures while traveling.
- If a clinician suspects clade I MPXV, they should contact the Pennsylvania Department of Health (DOH) or the local health department to discuss clade specific testing.
- If you have any questions, please call the DOH at 1-877-PA-HEALTH (1-877-724-3258) or your local health department.

Background

On September 23, 2024 the Centers for Disease Control and Prevention (CDC) issued a [Health Alert Network \(HAN\) Health Update](#) to provide additional information about the ongoing [outbreak of clade I monkeypox virus \(MPXV\)](#), the virus that causes mpox, in Central and Eastern Africa. This report is an update to the CDC HAN [Health Advisory 501](#) issued in December 2023 and the CDC HAN [Health Update 513](#) in August 2024.

MPXV has two distinct genetic clades: clade I (with subclades Ia and Ib) is [endemic to some countries in Central Africa](#), and clade II (with subclades IIa and IIb) is historically [endemic to some countries in West Africa](#). In 2023, the Democratic Republic of the Congo (DRC) reported [>14,000](#) suspected clade I mpox cases. As of September 18, 2024, [>21,000](#) suspected clade I mpox cases have been identified in DRC, its largest annual number on record. This includes [>700](#) deaths in a population of [>99](#) million people. Although the proportion of people impacted in DRC (population [>99](#) million) is relatively low, cases are more widespread than in any previously reported DRC outbreak. Clade Ia mpox cases are impacting the western part of DRC (particularly the rural *Équateur* Province). No cases of clade Ia mpox have been reported outside Central African countries where clade Ia MPXV is endemic. Clade Ib mpox cases are impacting the eastern part of DRC and have been spreading through regional travel.

MPXV transmission in countries where the virus is endemic is typically via exposure to infected wildlife with subsequent [person-to-person spread](#) via close contact (including intimate or sexual contact) with a person with mpox, or direct contact with their respiratory secretions (e.g., snot, mucus) or contaminated objects (e.g., bedding). During the global clade II outbreak, human-to-human transmission of mpox has been [predominantly spreading through sexual contact](#). Early data indicate that a large proportion of clade Ib mpox cases among adults also has been [associated with sexual contact](#), including via ongoing transmission believed to be occurring in some countries where the virus is not normally found.

Clade I MPXV has historically been associated with a higher proportion of severe infections compared to clade II MPXV; however, recent data suggest that previous severity estimates may have been too high. For example, a study conducted in DRC showed that routine supportive care was associated with a [lower clade Ia mpox case fatality rate \(<2%\)](#) than previously referenced (3%–11%). Clade Ib mpox cases appear to be clinically milder than clade Ia mpox cases; in addition, clade Ib mpox cases in DRC have been associated with a [lower case fatality rate than clade Ia](#) mpox cases. No clade I mpox deaths have been reported from countries where MPXV is not endemic at this time.

Travelers to DRC or other countries with sustained spread of clade I mpox, regardless of sexual orientation or gender identity, should be made aware of activities associated with cases and should be vaccinated with two doses of JYNNEOS if they anticipate certain sexual exposures while traveling.

In February 2023, the CDC Advisory Committee on Immunization Practices ([ACIP](#)) recommended a JYNNEOS vaccine series, with two doses administered 28 days apart, for people aged 18 years and older at risk of mpox during an mpox outbreak. This ACIP recommendation, which has been adopted by the CDC Director and is now official, leaves the determination of whether there is an mpox outbreak and the populations impacted to public health authorities. CDC has determined that [ongoing human-to-human transmission of clade I MPXV](#) in Central and East Africa is an outbreak and, in addition to general prevention strategies, recommends a JYNNEOS 2-dose vaccine series for

persons at risk for mpox via sexual exposure during travel to a [country with ongoing human-to-human transmission](#).

Active monitoring for mpox continues to occur in the United States. Although the United States continues to be affected by an ongoing [global outbreak of clade II mpox](#) that began in 2022, no domestic cases of clade I mpox have been identified in the United States at this time. Continue to follow CDC's [current vaccine guidance](#) to prevent clade II MPXV infection, which continues to circulate in the United States, and will also help protect against clade I MPXV.

Recommendations for Clinicians and Public Health Practitioners

During travel health visits:

- Discuss mpox prevention and risk reduction strategies with all travelers to countries with ongoing human-to-human transmission of clade I MPXV. Currently, these countries include Burundi, Central African Republic, DRC, Republic of the Congo, Rwanda, and Uganda. Note that ongoing transmission is not necessarily occurring in every country reporting mpox cases. An [updated list of the countries](#) with ongoing spread of clade I MPXV is available on the CDC website.
- Discuss patients' [sexual history](#) and travel plans, including if patients anticipate any sexual activity during travel. Up to [one in three travelers](#) will have sex with a new partner while on a trip.
- Advise travelers that mpox exposure risk is associated with sexual contact.
- Remind patients that mpox is not spread through casual contact, such as one might have in public spaces like markets, offices, or classrooms.
- Counsel patients on [activities that may increase risk](#) for MPXV exposure and risk reduction strategies if they have plans to travel to a [country where ongoing human-to-human transmission](#) of clade I MPXV is occurring. Travelers to affected countries should:
 - Avoid close contact with people who are sick with [signs and symptoms](#) of mpox, including skin or genital lesions.
 - Avoid contact with contaminated materials used by people who are sick, such as clothing, bedding, toothbrushes, sex toys, or materials used in healthcare settings.
- Advise patients about the risk for mpox exposure through sexual contact (regardless of sexual orientation or gender identity) associated with clade I MPXV.
- Recommend vaccination with the 2-dose JYNNEOS vaccine series to any adult, regardless of gender identity or sexual orientation, if:
 - They are traveling to a country where clade I MPXV is spreading between people, AND
 - They anticipate experiencing any of the following:
 - 1) Sex with a new partner
 - 2) Sex at a commercial sex venue, like a sex club or bathhouse
 - 3) Sex in exchange for money, goods, drugs, or other trade
 - 4) Sex in association with a large public event, such as a rave, party, or festival
- Recommend starting, if possible, the mpox vaccine series at least 6 weeks before travel begins, since two doses should be given 28 days apart and it takes 14 more days for immunity to peak.
- Emphasize [risk reduction strategies](#) in conversation with patients who are not eligible for vaccination, or who do not present in time to receive the two recommended vaccine doses 28 days apart

- Advise patients that two vaccine doses are more effective than one dose.
 - Two doses of JYNNEOS can [prevent mpox and may reduce the severity](#) of symptoms in people with mpox.
 - A [multijurisdictional study](#) conducted in 2022–2023 in the United States identified significant JYNNEOS vaccine effectiveness against clade IIb mpox: 75% after one dose and 86% after two doses.
- Consult CDC’s [mpox vaccine finder](#) if your facility doesn’t have mpox vaccine.
- Counsel patients who might be at risk exclusively from day-to-day household contact or patient care about risk reduction strategies other than vaccination.
- Continue to follow CDC’s [current vaccine guidance](#) to prevent clade II MPXV infection, which continues to circulate in the United States, and will also help protect those individuals from clade I MPXV.

Recommendations for Travelers

When traveling to a country with ongoing human-to-human clade I MPXV transmission:

- Learn more about which activities may [increase your risk of exposure](#) when you travel to a country where [clade I MPXV is spreading](#).
- No matter what your plans are when you visit, if you’re traveling to a country that has an ongoing clade I MPXV outbreak, [protect yourself and others from mpox](#), including by:
 - Avoiding close contact with people who are sick with [signs and symptoms of mpox](#), including skin or genital lesions.
 - Avoiding contact with contaminated materials used by people who are sick, such as clothing, bedding, toothbrushes, sex toys, or materials used in healthcare settings.
- Talk to your provider about getting vaccinated with two doses of JYNNEOS if:
 - You are traveling to a country where clade I MPXV is spreading between people, AND
 - You anticipate experiencing any of the following:
 - 1) Sex with a new partner
 - 2) Sex at a commercial sex venue, such as a sex club or bathhouse
 - 3) Sex in exchange for money, goods, drugs, or other trade
 - 4) Sex in association with a large public event, such as a rave, party, or festival
- Find a place to get vaccinated near you with CDC’s [mpox vaccine finder](#).
- Get your first mpox vaccine at least 6 weeks before traveling, if possible. After completing your first and second vaccine doses, which are given 4 weeks apart, it takes about 2 more weeks to get the best protection against mpox.
- Get two doses of JYNNEOS if you are [eligible to get mpox vaccine](#) because of the clade IIb outbreak that began in 2022 and you’ve never had mpox before.
- Know that getting two doses of JYNNEOS is expected to protect you from orthopoxviruses including both mpox clades. If you were already vaccinated with two doses, or if you previously recovered from mpox, you do not need any mpox vaccine doses now.
- Take steps to [protect yourself and others from mpox](#) even if you are fully vaccinated or have had mpox before.

If a clinician suspects a returning traveler has clade I mpox, they should contact the Pennsylvania Department of Health (DOH) or the local health department to discuss clade specific testing for clade I MPXV.

For More Information

For Clinicians and Public Health Partners

- [Clade I Mpox Outbreak Originating in Central Africa | Mpox | CDC](#)
- [Ongoing Clade II Mpox Global Outbreak | Mpox | CDC](#)
- [Information For Healthcare Professionals | Mpox | CDC](#)
- [Information for Health Departments | Mpox | CDC](#)
- [Sex & Travel | CDC Yellow Book 2024](#)
- [Guide to Taking a Sexual History | CDC](#)
- [Mpox Briefing for Providers Who Care for Pediatric Populations | HHS](#)
- CDC Poxvirus and Rabies Branch: poxvirus@cdc.gov or, for emergencies, CDC's 24/7 Emergency Operations Center (EOC): 770-488-7100
- Health Department Contacts: [After Hours/Epi-on-Call Contact Lists – Council of State and Territorial Epidemiologists \(cste.org\)](#)

For the Public

- [Mpox in the United States and Around the World: Current Situation | Mpox | CDC](#)
- [About Mpox | Mpox | CDC](#)
- [Mpox Vaccination | Mpox | CDC](#)
- [Preventing | Mpox | CDC](#)
- [September 2024 Travel Health Notice: Clade I Mpox in Central and Eastern Africa](#)
- General inquiries: CDC-INFO (1-800-232-4636)

If you have any questions, please call DOH at 1-877-PA-HEALTH (1-877-724-3258) or your local health department.

Individuals interested in receiving further PA-HANs are encouraged to register at [HAN Notification Registration \(mir3.com\)](#)

Categories of Health Alert messages:

Health Alert: conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: provides important information for a specific incident or situation; may not require immediate action.

Health Update: provides updated information regarding an incident or situation; unlikely to require immediate action.

This information is current as of September 27, 2024, but may be modified in the future. We will continue to post updated information regarding the most common questions about this subject.